Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at

Vinay Prasad*, Jeffery A. Goldstein

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Background Although participation in cancer clinical trials is low, little is known about the number of available clinical trials, and open spots for patients. Moreover, it is unclear what the relationship is between clinical trial openings and the incidence and mortality of cancer subtypes. Methodology We identified the number of phase I, phase II and phase III registered at by cancer (tumour) type. All counts were over the preceding 5 years (2008-2013). We compared these counts against the incidence and prevalence of disease reported by Surveillance, Epidemiology and End Results (SEER) database for 32 common cancers. Results From 2008 to 2013, 3879 phase I trials, 4982 phase II trials and 1379 phase III trials concerning a cancer subtype were registered in These trials had a cumulative proposed recruitment of 203,396, 421,502 and 697,787 patients, respectively. Trial enrolment varied by tumour type, with both over and under-representation occurring. Conclusion Opportunities to enrol in clinical trials vary by phase and tumour type. Oncologists must remain committed to clinical trials.

Original languageEnglish (US)
Pages (from-to)2718-2723
Number of pages6
JournalEuropean Journal of Cancer
Issue number17
StatePublished - 2015


  • Burden of disease
  • Cancer clinical trials
  • Cancer trials
  • Cancer trials portfolio
  • Phase I, phase II and phase III

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Clinical trial spots for cancer patients by tumour type: The cancer trials portfolio at'. Together they form a unique fingerprint.

Cite this